pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,430 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1853Endpoints1441Fierce Biotech760BioSpace745BioPharma Dive544raps249onclive165fda recalls
therapy area
allOncology12827Rare Disease3326Immunology2981Cardiology2845Hematology2283Pulmonology2231Vaccines
  • FDA rejects Summit Therapeutics' PD-1/VEGF bispecific ivonescimab after Phase 3 failure
    The U.S. Food and Drug Administration declined to grant approval for ivonescimab, a bispecific antibody that targets PD‑1 and VEGF and was being developed by Summit Therapeutics in collaboration wi…
    BioSpace · 1h agoRegulatoryNegative↗ source
  • Priavoid’s Alzheimer’s drug misses primary goal in phase 2 trial, shows later cognitive benefit signal
    German biotech Priavoid reported that its oral all-D-peptide candidate, PRI-002, did not achieve the primary efficacy endpoint in the phase 2 PRImus-AD study of patients with mild cognitive impairm…
    Fierce Biotech · 8h agoNegative readoutNegative↗ source
← prev
page 1 of 178
next →
118
fda medwatch114
globenewswire health73
fda press61
1844
Psychiatry & CNS1229
Ophthalmology1129
Endocrinology & Metabolism806
Pain789
Nephrology782
  • Cognito Therapeutics' Phase 3 HOPE Study Misses Primary Goal but Shows Promise in Mild Alzheimer’s Patients
    Cognito Therapeutics announced that its phase 3 HOPE trial of Spectris AD, a home-based device delivering light and sound stimulation, did not achieve its primary efficacy endpoint. The trial enro…
    Fierce Biotech · 9h agoNegative readoutNeutral↗ source
  • Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challenges
    Acquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
    BioSpace · 7h agoDealNeutral↗ source
  • FDA clears Medtronic's MiniMed Fit tubeless insulin pump
    MiniMed, a Medtronic unit, announced that the FDA has granted clearance for its new tubeless insulin pump called MiniMed Fit. The device is designed to be worn for up to seven days and holds a 300…
    Fierce Biotech · 9h agoApprovalPositive↗ source
  • Merck halts $2.7 billion BTK inhibitor program after negative phase 3 data
    Merck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…
    Fierce Biotech · 9h agoNegative readoutNegative↗ source
  • Big Pharma execs urge biotech firms to be transparent and patient to win deals
    At Fierce Biotech's London Life Sciences Week, representatives from five major pharmaceutical companies shared how they evaluate biotech partners. Bayer's head of business development warned that…
    Fierce Biotech · 10h agoDealNeutral↗ source
  • White House withdraws Heidi Overton’s FDA commissioner nomination amid Senate opposition
    The White House pulled the nomination of Heidi Overton for FDA commissioner just hours before the Senate Health, Education, Labor, and Pensions (HELP) committee was set to vote. Overton, who serve…
    BioSpace · 10h agoRegulatoryNegative↗ source
  • White House withdraws Heidi Overton's nomination to lead the FDA amid Senate Republican concerns
    The White House announced it is withdrawing its nominee, Heidi Overton, for FDA commissioner. Overton, a preventive care physician who previously served in the Trump administration, faced resistan…
    STAT · 12h agoRegulatoryNegative↗ source
  • Why comparing every new employer to your last one can hurt your influence
    Executive coach Angela Justice advises professionals not to treat their former workplace as the standard for every new job. She says the habit can cloud judgment and reduce a person's influence. W…
    BioSpace · 7h agoNeutral↗ source
  • FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancers
    The U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…
    BioPharma Dive · 19h agoApprovalPositive↗ source
  • Isomorphic Labs raises record $5 billion in Series C, doubling its May funding
    Isomorphic Labs, an AI-driven drug design company, announced a $5 billion Series C financing, the largest private biotech raise ever and more than double its $2.1 billion Series B from May. The ro…
    BioSpace · 20h agoDealPositive↗ source
  • Vertex awaits FDA decision on povetacicept for IgA nephropathy, analysts expect approval
    Vertex Pharmaceuticals is awaiting an FDA ruling this month on its investigational drug povetacicept, being evaluated for the treatment of IgA nephropathy. Analysts, including Myles Minter of Will…
    BioSpace · 21h agoRegulatoryPositive↗ source
  • Sellas cancer vaccine cuts death risk by 41% in late-stage AML trial
    Sellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…
    BioSpace · 22h agoPositive readoutPositive↗ source
  • Isomorphic Labs secures $5 billion Series C, doubling its recent $2.1 billion raise
    Isomorphic Labs, an AI‑driven drug discovery startup spun out of DeepMind, announced a $5 billion Series C financing, marking its second multibillion‑dollar round within six months. The funding fo…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Eli Lilly inks $5.9 billion partnership with Stipple Bio to develop precision oncology drugs
    Eli Lilly has announced a partnership with Stipple Bio that could be worth up to $5.9 billion. The collaboration will focus on oncology drug candidates designed to target tumor cells more precisely…
    Fierce Biotech · 1d agoDealPositive↗ source
  • White House withdraws Heidi Overton’s FDA nomination hours before Senate vote
    The White House has reportedly withdrawn the nomination of Dr. Heidi Overton, who was slated to become the FDA’s next commissioner, just hours before the Senate HELP Committee was set to vote. Ove…
    Fierce Biotech · 16h agoRegulatoryNegative↗ source
  • AriBio's AR1001 shows 31% slower cognitive decline in monotherapy Phase 3 trial
    AriBio presented data at the 2026 Clinical Trials on Alzheimer's Disease conference indicating its candidate AR1001 slowed cognitive decline compared with placebo in patients not taking other Alzhe…
    BioSpace · 22h agoPositive readoutPositive↗ source
  • FDA approves Roche's new breast cancer drug, poised to become its top-selling product
    The U.S. Food and Drug Administration has granted approval to a new breast cancer therapy developed by Roche. This clearance paves the way for the drug's market launch. Roche says the medication c…
    STAT · 22h agoApprovalPositive↗ source
  • Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trial
    Sellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…
    STAT · 1d agoPositive readoutPositive↗ source
  • FDA rejects Summit’s ivonescimab, citing China‑centric data and missed survival benefit
    The FDA sent Summit Therapeutics a complete response letter on Nov 13, rejecting its PD‑1×VEGF bispecific antibody ivonescimab. Reviewers said the pivotal HARMONi trial was dominated by patients f…
    Fierce Biotech · 20h agoCRLNegative↗ source
  • Genetix Biotherapeutics reports $327M YTD sales and projects $500M full-year revenue, marking profitability
    Genetix Biotherapeutics, the former bluebird bio, announced that it has become profitable, reporting $327 million in U.S. net sales year‑to‑date and forecasting total 2026 sales of about $500 milli…
    BioSpace · 1d agoEarningsPositive↗ source
  • Capsida proposes new monkey testing framework after fatal gene therapy trial for brain disease
    Researchers presented investigations into a patient death that occurred in a gene therapy trial for a brain disease, which had raised concerns in the field. While the exact cause of death was not…
    STAT · 1d agoNegative readoutNegative↗ source
  • HHS finalizes HIPAA privacy rule update to boost patient access to medical records
    The Department of Health and Human Services announced a final rule change to the HIPAA privacy regulations, marking the first major revision in nearly six years. The updates are designed to simpli…
    STAT · 17h agoRegulatoryPositive↗ source
  • GOP and MAHA leaders dispute FDA nominee Heidi Overton's vaping policy record
    Washington officials are locked in a public dispute over the nomination of Heidi Overton to lead the Food and Drug Administration. The controversy highlights growing divisions within the Republican…
    STAT · 18h agoRegulatoryNegative↗ source